Biomatter

About Biomatter

Biomatter is a synthetic biology company that creates novel proteins and enzymes for applications in healthcare, agriculture, and sustainable manufacturing. The company was co-founded in 2018 by Laurynas Karpus, Vykintas Jauniškis, Irmantas Rokaitis, Donatas Repečka, and Professor Rolandas Meškys, who met at Vilnius University's Institute of Biotechnology. With a background in biophysics and molecular biology, CEO Laurynas Karpus leads the company's efforts. The founders were named to the Forbes "30 Under 30 Europe" list for Science & Healthcare.

The core of Biomatter's offering is its Intelligent Architecture™ platform, which utilizes generative artificial intelligence and physics-based algorithms to design enzymes from the ground up (de novo). This "bottom-up" approach contrasts with traditional methods that rely on modifying existing natural enzymes, a process that is often slow and limited in scope. By defining the desired function first, the platform can generate entirely new, purpose-built enzymes optimized for specific industrial processes. This method shortens the development cycle from years to weeks.

Biomatter's business model is centered on partnerships with global companies to co-develop unique, enzyme-based products and technologies, offering flexible collaboration and risk-sharing models. Its client base includes major corporations such as Thermo Fisher Scientific, BASF, and Neogen. Notable projects include a collaboration with Kirin to efficiently produce Human Milk Oligosaccharides (HMOs) for infant nutrition and a partnership with Neogen to advance food safety solutions. The company has also worked with ArcticZymes Technologies. Revenue is generated through these partnerships, which span industries from life sciences and food production to chemical biomanufacturing. To date, the company has raised $8.86M in funding, including a €6.5 million seed round in August 2024 led by Inventure and UVC Partners.